U.S.
      SECURITIES AND EXCHANGE COMMISSION


Washington,
      D.C. 20549







FORM
      10-QSB


(Mark
      One)




x QUARTERLY
      REPORT
      UNDER SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE ACT OF 1934




For
      the
      quarterly period ended October 31, 2007




o TRANSITION
      REPORT
      UNDER SECTION 13 OR 15(D) OF THE EXCHANGE ACT




For
      the
      transition period from to




Commission
      File Number: 000-52836




Lifesciences
      Opportunities Incorporated


(Exact
      name of Small Business Issuer as specified in its Charter)




Florida
            20-0594204(State
                or other jurisdiction of
            (I.R.S.
                Employerincorporation
                or organization)
            Identification
                No.)




925
      S.
      Federal Highway, Suite 600, Boca Raton, Florida 33432


(Address
      of principal executive offices)




561-208-2929


(Issuer's
      telephone number)







(Former
      Name, former address and former fiscal year, if changed since last
      Report.)




Check
      mark whether the Issuer (1) has filed all reports required to be filed by
      Section 13 or 15 (d) of the Securities Exchange Act of 1934 during the past
      12
      months (or for such shorter period that the registrant was required to file
      such
      reports), and (2) has been subject to such filing requirements for the past
      90
      days. Yes x No
o




Indicate
      by check mark whether the registrant is a shell company (as defined in Rule
      12b-2 of the Exchange Act). Yes x No
o




APPLICABLE
      ONLY TO CORPORATE ISSUERS




State
      the
      number of shares outstanding of each of the issuer's classes of common equity,
      as of the latest practicable date: January 15, 2008, we had 40,000 shares of
      our
      Common Stock outstanding.




Transitional
      Small Business Disclosure Format (Check one): Yes o No x





**INDEX**




**PART
                I. FINANCIAL INFORMATION**
            **1****Item
                1.**
            **Financial
                Statements.**
            **1****Item
                2.**
            **Management's
                Discussion and Analysis of Financial Condition and Plan of
                Operations**
            **2****Item
                3.**
            **Controls
              and
              Procedures**
            **3****PART
                II. OTHER INFORMATION**
            **5****Item
                1.**
            **Legal
                Proceedings**
            **5****Item
                2.**
            **Unregistered
                Sales of Equity Securities and Use of Proceeds**
            **5****Item
                3.**
            **Default
                Upon Senior Securities**
            **5****Item
                4.**
            **Submission
                of Matters to a Vote of Securities**
            **5****Item
                5.**
            **Other
                Information**
            **5****Item
                6.**
            **Exhibits**
            **5****Signatures**
            **6**









**PART
      I. FINANCIAL INFORMATION**




**Item
      1.**  **Financial
      Statements.**






LIFESCIENCES
        OPPORTUNITIES INCORPORATED
  CONDENSED
        FINANCIAL STATEMENTS
 
 Table
        of
        Contents
 
 
 Condensed
                  Balance Sheets
              F
                  -
                  2Condensed
                  Statements of Operations
              F
                  -
                  3Condensed
                  Statements of Changes in Shareholders’ Deficit
              F
                  -4Condensed
                  Statements of Cash Flows
              F
                  -
                  5Notes
                  to the Condensed Financial Statements
              F
                  -
                  6-10
 
 
 1
 LIFESCIENCES
                    OPPORTUNITIES INCORPORATEDCONDENSED
                    BALANCE SHEETS
   October
                    31,
                
                January
                    31,2007
                
                2007(Unaudited)
                
                (Audited)ASSETSCURRENT
                    ASSETSCash
                
                $
                115
                
                $
                6TOTAL
                    CURRENT ASSETS
                
                
                115
                
                
                6OTHER
                    ASSETSRestricted
                    cash
                
                
                30,405
                
                
                30,122TOTAL
                    ASSETS
                
                $
                30,520
                
                $
                30,128LIABILITIES
                    AND SHAREHOLDERS' DEFICITCURRENT
                    LIABILITIESAccounts
                    payable
                
                $
                27,740
                
                $
                3,894Accrued
                    expenses
                
                
                5,486
                
                
                15,225Loan
                    from shareholders
                
                
                38,376
                
                
                9,100TOTAL
                    CURRENT LIABILITIES
                
                
                71,602
                
                
                28,219TOTAL
                    LIABILITIES
                
                
                71,602
                
                
                28,219Commitments
                    & Contingencies
                
                
                -
                
                
                -SHAREHOLDERS'
                    DEFICITCommon
                    stock, $0.0001 par value,80,000,000
                    shares authorized,40,000
                    shares issued and outstanding
                
                
                4
                
                
                4Additional
                    paid-in capital
                
                
                4,996
                
                
                4,996Common
                    stock subscribed
                
                
                30,004
                
                
                30,004Accumulated
                    deficit
                
                
                (76,086
                )
                
                (33,095
                )TOTAL
                    SHAREHOLDERS' DEFICIT
                
                
                (41,082
                )
                
                1,909TOTAL
                    LIABILITIESAND
                    SHAREHOLDERS' DEFICIT
                
                $
                30,520
                
                $
                30,128
   The
            accompanying notes are an integral part of these financial
            statements.
 F-2
 LIFESCIENCES
                  OPPORTUNITIES INCORPORATEDCONDENSED
                  STATEMENTS OF OPERATIONS
   For
                  the THREE months ended
              
              For
                  the NINE months endedOctober
                  31,
              
              October
                  31,2007
              
              2006
              
              2007
              
              2006(Unaudited)
              
              (Unaudited)REVENUES
              
              $
              -
              
              $
              -
              
              $
              -
              
              $
              -OPERATING
                  EXPENSES
              
              
              38,110
              
              
              3,710
              
              
              43,334
              
              
              16,104LOSS
                  FROM OPERATIONS
              
              
              (38,110
              )
              
              (3,710
              )
              
              (43,334
              )
              
              (16,104
              )OTHER
                  INCOME (EXPENSES)
              
              
              228
              
              
              8
              
              
              343
              
              
              8LOSS
                  BEFORE TAXES
              
              $
              (37,882
              )
              $
              (3,702
              )
              $
              (42,991
              )
              $
              (16,096
              )Weighted
                  average commonshares
                  outstanding -basic and diluted
              
              
              40,000
              
              
              40,000
              
              
              40,000
              
              
              40,000NET
                  LOSS PER SHARE - basic and diluted
              
              $
              (0.95
              )
              $
              (0.09
              )
              $
              (1.07
              )
              $
              (0.40
              )







The
        accompanying notes are an integral part of these financial
        statements.
 F-3


LIFESCIENCES
                  OPPORTUNITIES INCORPORATEDCONDENSED
                  STATEMENTS OF CHANGES IN SHAREHOLDERS'
                  DEFICIT
   Common
                  Stock
              
              
              
              Common80,000,000
                  shares authorized
              
              Additional
              
              StockShares
              
              Par
                  Value
              
              Paid-in
              
              Subscriptions
              
              AccumulatedIssued
              
              $.0001
                  per share
              
              Capital
              
              Received
              
              Deficit
              
              TotalBALANCE
                  - JANUARY 31, 2006 (Audited)
              
              
              40,000
              
              $
              4
              
              $
              4,996
              
              $
              -
              
              $
              (9,460
              )
              $
              (4,460
              )Proceeds
                  from stock subscriptions
              
              
              
              
              
              -
              
              
              -
              
              
              30,004
              
              
              -
              
              
              30,004Net
                  Loss
              
              
              
              
              
              -
              
              
              -
              
              
              -
              
              
              (23,635
              )
              
              (23,635
              )BALANCE
                  - JANUARY 31, 2007 (Audited)
              
              
              40,000
              
              $
              4
              
              $
              4,996
              
              $
              30,004
              
              $
              (33,095
              )
              $
              1,909Net
                  Loss
              
              
              
              
              
              -
              
              
              -
              
              
              -
              
              
              (42,991
              )
              
              (42,991
              )BALANCE
                  - OCTOBER 31, 2007 (Unaudited)
              
              
              40,000
              
              $
              4
              
              $
              4,996
              
              $
              30,004
              
              $
              (76,086
              )
              $
              (41,082
              )


The
        accompanying notes are an integral part of these financial
        statements.
 F-4
  LIFESCIENCES
                  OPPORTUNITIES INCORPORATEDCONDENSED
                  STATEMENTS OF CASH FLOWS
   For
                  the NINE months endedOctober
                  31,2007
              
              2006(Unaudited)
              
              (Unaudited)Cash
                  flows from operating activitiesNet
                  loss
              
              $
              (42,991
              )
              $
              (16,096
              )Adjustments
                  to reconcile net loss to netcash
                  used in operating activities:Increase
                  in restricted cash
              
              
              (283
              )
              
              (17,932
              )Increase
                  in accounts payable
              
              
              23,846
              
              
              3,894Decrease
                  in accrued expenses
              
              
              (9,739
              )
              
              7,500Net
                  cash used by operating activities
              
              
              (29,167
              )
              
              (22,634
              )Cash
                  flows from financing activitiesProceeds
                  from shareholder loan
              
              
              29,276
              
              
              4,600Issuance
                  of common stock subscriptions
              
              
              -
              
              
              18,000Net
                  cash provided by financing activities
              
              
              29,276
              
              
              22,600NET
                  INCREASE (DECREASE) IN CASH
              
              
              109
              
              
              (34
              )CASH
                  AT BEGINNING OF PERIOD
              
              
              6
              
              
              40CASH
                  AT END OF PERIOD
              
              $
              115
              
              $
              6




The
        accompanying notes are an integral part of these financial
        statements.


F-5


LIFESCIENCES
        OPPORTUNITIES INCORPORATED
 NOTES
        TO
        THE CONDENSED FINANCIAL STATEMENTS






NOTE
      1 -
      ORGANIZATION AND GOING CONCERN





Lifesciences
      Opportunities, Inc. (the “Company”) was incorporated under the laws of the State
      of Florida on January 12, 2004, to engage in any lawful corporate undertaking,
      including, but not limited to, selected mergers and acquisitions. The Company
      has had no operations to date other than issuing shares to its original
      shareholder.





The
      Company has been formed to provide a method for a foreign or domestic private
      company to become a reporting ("public") company whose securities are qualified
      for trading in the United States secondary market.





The
      Company will attempt to locate and negotiate with a business entity for the
      combination of that target company with us. The combination will normally take
      the form of a merger, stock-for-stock exchange or stock-for-assets exchange.
      No
      assurances can be given that we will be successful in locating or negotiating
      with any target company.





These
      financial statements have been prepared assuming that the Company will continue
      as a going concern. The Company’s independent accountants have included a “going
      concern” paragraph in their audit report accompanying the financial statements
      for the year ended January 31, 2007 that cautions users of the statements that
      the Company needs to seek new sources or methods of financing or revenue to
      pursue its business strategy. The financial statements do no include any
      adjustments that might result from the outcome of this uncertainty. The Company
      anticipates that future revenue will be sufficient to cover certain operating
      expenditures, and, in the interim, will continue to pursue additional capital
      investment. However, there can be no assurance that the Company will be able
      to
      successfully acquire the necessary capital investment or revenue to continue
      their on-going efforts and continue operations. These factors, among others,
      create an uncertainty about the Company’s ability to continue as a going
      concern.





Interim
      Financial Statements





The
      interim financial statements presented herein are unaudited and have been
      prepared pursuant to the rules and regulations of the US Securities and Exchange
      Commission (SEC). Certain information and footnote disclosures normally included
      in financial statements prepared in accordance with accounting principles
      generally accepted in the United States of America have been condensed or
      omitted pursuant to such rules and regulations. The interim financial statements
      should be read in conjunction with the Company's audited financial statements,
      notes and accounting policies included in the Company's annual report on Form
      10KSB for the year ended January 31, 2007 as filed with the SEC. In the opinion
      of management, all adjustments (consisting only of normal recurring adjustments)
      which are necessary to provide for a fair presentation of financial position as
      of October 31, 2007 and the related operating results and cash flows for the
      interim period presented have been made. The results of operations, for the
      period presented are not necessarily indicative of the results to be expected
      for the year.





F-6


LIFESCIENCES
        OPPORTUNITIES INCORPORATED
 NOTES
        TO
        THE CONDENSED FINANCIAL STATEMENTS


NOTE
      2 -
      SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES





Revenue
      Recognition





The
      Company has adopted and follows the guidance provided in the Securities and
      Exchange Commission’s Staff Accounting Bulletin (“SAB”) No. 104, which provides
      guidance on the recognition, presentation and disclosure of revenue in financial
      statements.





Use
      of
      Estimates





The
      preparation of financial statements in conformity with generally accepted
      accounting principles requires management to make estimates and assumptions
      that
      affect the reported amounts of assets and liabilities, and disclosure of
      contingent assets and liabilities, at the date of these financial statements,
      and the reported amounts of revenues and expenses during the reporting period.
      Actual results could differ from those estimates.





Cash





The
      Company considers all highly liquid debt securities purchased with original
      or
      remaining maturities of three months or less to be cash equivalents. The
      carrying value of cash equivalents approximates fair value.





Income
      Taxes





Effective
      February 1, 2007, the Company adopted Financial Accounting Standards Board
      Interpretation (FIN) No: 48, “Accounting for Uncertainty in Income Taxes, an
      interpretation of Financial Accounting Standards Board (FASB) Statement on
      Financial Accounting Standards (SFAS) No. 109, Accounting for Income Taxes”. The
      interpretation addresses the determination of whether tax benefits claimed
      or
      expected to be claimed on a tax return should be recorded in the financial
      statements. Under FIN 48, the Company may recognize the tax benefit from an
      uncertain tax position only if it is more likely than not that the tax position
      will be sustained on examination by the taxing authorities, based on the
      technical merits of the position. The tax benefits recognized in the financial
      statements from such a position should be measured based on the largest benefit
      that has a greater than fifty percent likelihood of being realized upon ultimate
      settlement. FIN 48 also provides guidance on derecognition, classification,
      interest and penalties on income taxes, accounting in interim periods and
      requires increased disclosures. At the date of adoption, and as of October
      31,
      2007, the Company does not have a liability for unrecognized tax
      benefits.





The
      Company files income tax returns in the U.S. federal jurisdiction and various
      states. The Company is subject to U.S. federal or state income tax examinations
      by tax authorities for the years after 2004. During the periods open to
      examination, the Company has Net Operating Losses (NOLs) and tax credit carry
      forwards for U.S. federal and state tax purposes that have attributes from
      closed periods. Since these NOLs and tax credit carry forwards may be utilized
      in future periods, they remain subject to examination.





F-7
 
 LIFESCIENCES
          OPPORTUNITIES INCORPORATED
 NOTES
          TO
          THE CONDENSED FINANCIAL STATEMENTS


The
      Company’s policy is to record interest and penalties on uncertain tax provisions
      as income tax expense. As of October 31, 2007, the Company has no accrued
      interest or penalties related to uncertain tax positions.





Loss
      Per Share





The
      Company computes basic and diluted loss per share amounts pursuant to Statement
      of Financial Accounting Standards (SFAS) No. 128, “Earnings per Share.” There
      are no potentially dilutive shares outstanding and, accordingly, dilutive per
      share amounts are the same as basic per share amounts.





Recent
      Accounting Pronouncements




In
      February 2007, the FASB issued SFAS No. 159, "The Fair Value Option for
      Financial Assets and Financial Liabilities -- Including an amendment of FASB
      Statement No. 115" (FAS 159), which becomes effective for the Company on
      February 1, 2008, permits companies to choose to measure many financial
      instruments and certain other items at fair value and report unrealized gains
      and losses in earnings. Such accounting is optional and is generally to be
      applied instrument by instrument. The Company does not anticipate that the
      election, of this fair-value option, will have a material effect on its
      financial condition, results of operations, cash flows or
      disclosures.




In
      September 2006, the FASB issued SFAS No. 157, "Fair Value Measurements" (SFAS
      157). SFAS 157 provides guidance for using fair value to measure assets and
      liabilities. SFAS 157 addresses the requests from investors for expanded
      disclosure about the extent to which companies measure assets and liabilities
      at
      fair value, the information used to measure fair value and the effect of fair
      value measurements on earnings. SFAS 157 applies whenever other standards
      require (or permit) assets or liabilities to be measured at fair value, and
      does
      not expand the use of fair value in any new circumstances. SFAS 157 is effective
      for financial statements issued for fiscal years beginning after November 15,
      2007 and will be adopted by the Company in the first quarter of fiscal year
      2009. The Company is unable at this time to determine the effect that its
      adoption of SFAS 157 will have on its results of operations and financial
      condition.




NOTE
      3 -
      RESTRICTED CASH





Restricted
      cash as of October 31, 2007 is comprised of $30,405 received from stock
      subscriptions and placed in an escrow account subject to the provisions of
      the
      initial public offering as described in Note 6.




F-8


LIFESCIENCES
        OPPORTUNITIES INCORPORATED
 NOTES
        TO
        THE CONDENSED FINANCIAL STATEMENTS






NOTE
      4 -
      RELATED PARTY TRANSACTIONS





The
      loans
      from shareholders as of October 31, 2007 and January 31, 2007 are $38,376 and
      $10,100, respectively. The notes are interest free and the Company imputed
      interest in accordance with the provisions of Accounting Principles Board
      Opinion (APBO) No. 21 Interest on Receivables and Payables. Accordingly, the
      interest expense for the periods ended October 31, 2007 and January 31, 2007
      are
      $476 and $510 respectively. The average interest rate used for the periods
      was
      4.42%.





NOTE
      5 -
      ACCRUED EXPENSES





Accrued
      expenses as of October 31, 2007 and January 31, 2007 are as follows





October
                  31, 2007
              
              January
                  31, 2007Audit
                  fees
              
              $
              4,500
              
              $
              12,500Legal
                  fees
              
              
              -
              
              
              2,215Interest
                  expenses
              
              $
              986
              
              $
              510Total
                  accrued expenses
              
              $
              5,486
              
              $
              15,225





NOTE
      6-
      COMMON STOCK SUBSCRIBED





In
      June,
      2006 the Company conducted a "blank check" offering subject to Rule 419 of
      Regulation C as promulgated by the U.S. Securities and Exchange Commission
      (SEC)
      under the Securities Act of 1933, as amended. The offering proceeds and the
      securities to be issued to investors must be deposited in an escrow account.
      While held in the escrow account, the deposited securities may not be traded
      or
      transferred. Except for an amount up to 10% of the deposited funds otherwise
      releasable under Rule 419, the deposited funds and the deposited securities
      may
      not be released until an acquisition meeting certain specified criteria has
      been
      consummated and a sufficient number of investors reconfirm their investment
      in
      accordance with the procedures set forth in Rule 419. Pursuant to these
      procedures, a new prospectus, which describes an acquisition candidate and
      its
      business and includes audited financial statements, will be delivered to all
      investors. The Company must return the pro rata portion of the deposited funds
      to any investor who does not elect to remain an investor. Unless a sufficient
      number of investors elect to remain investors, all investors will be entitled
      to
      the return of a pro rata portion of the deposited funds (plus interest, if
      any)
      and none of the deposited securities will be issued to investors. In the event
      an acquisition is not consummated within 18 months of the effective date of
      this
      prospectus, the deposited funds will be returned on a pro rata basis to all
      investors.





The
      filing was declared to be effective by SEC on June 14, 2006. The Company offered
      10,000 shares through this offering of which 5,000 shares were subscribed for
      as
      of October 31, 2007. The Company placed the entire proceeds of $30,004 from
      the
      sale of the shares in an escrow account and the proceeds are subject to
      compliance with Rule 419.




F-9


LIFESCIENCES
          OPPORTUNITIES INCORPORATED
 NOTES
          TO
          THE CONDENSED FINANCIAL STATEMENTS


NOTE
      7 -
      SUBSEQUENT EVENTS





In
      December 2007, the Company returned all the funds received from the investors
      as
      described under note 6 as the Company was unable to comply with the requirements
      of Rule 419; specifically the Company was unable to complete an acquisition
      on
      or before December 14, 2007. The shares issued and held in escrow were returned
      to treasury.














F-10


**Item
                2.**
            **Management's
                Discussion and Analysis of Financial Condition and Plan of
                Operations**




**Forward-Looking
      Statements**




The
      following discussion of the financial condition and results of operations should
      be read in conjunction with our financial statements and related notes thereto.
      The following discussion contains forward-looking statements. Lifesciences
      Opportunities Incorporated is referred to herein as "the Company", "we" or
      "our.” The words or phrases "would be," "will allow," "intends to," "will likely
      result," "are expected to," "will continue," "is anticipated," "estimate,"
      "project," or similar expressions are intended to identify "forward-looking
      statements". Such statements include those concerning our expected financial
      performance, our corporate strategy and operational plans. Actual results could
      differ materially from those projected in the forward-looking statements as
      a
      result of a number of risks and uncertainties. Statements made herein are as
      of
      the date of the filing of this Form 10-QSB with the Securities and Exchange
      Commission and should not be relied upon as of any subsequent date. Unless
      otherwise required by applicable law, we do not undertake, and we specifically
      disclaim any obligation, to update any forward-looking statements to reflect
      occurrences, developments, unanticipated events or circumstances after the
      date
      of such statement.




**Plan
      of Operations**




The
      Company intends to seek to acquire assets or shares of an entity actively
      engaged in a business that generates revenues, in exchange for its securities.
      During December 2006, the Company closed its 419 offering and collected gross
      proceeds of $30,000. The funds were held with an escrow agent. Under the 419
      Rule, the shareholders were entitled to have monies returned to them if eighteen
      months pass without completing a merger or acquisition under the requirements
      of
      Rule 419. Subsequent to the date of this report, we were notified by the
      Securities and Exchange Commission that we would not comply with Rule 419 and
      should therefore return all funds. The Company has returned all monies to the
      investors and the shares issuable to the shareholders were returned to treasury.




As
      reported on Form 8-K Current Report filed on October 1, 2007, the Company
      entered into an agreement and plan of merger ("Merger Agreement") with Dr.
      TATTOFF, LLC, a California limited liability company ("TATTOFF") dated September
      7, 2007, whereby TATTOFF will be merged into the Company (the “Merger”). Under
      the terms of the Merger Agreement, the Company will issue up to 12,500,000
      shares of its restricted common stock and common stock purchase warrants to
      purchase up to an aggregate of 2,908,500 shares of the Company's common stock,
      exercisable at $1.25 per share, subject to adjustment. The completion of the
      merger will be subject to satisfaction or waiver of additional conditions
      described in the Merger Agreement. On February 1, 2008, the Company and TATTOFF
      entered into a Second Amendment to the Merger Agreement (“Second Amendment”),
      amending the Merger Agreement. The Second Amendment extends the termination
      date
      of the Merger Agreement from February 1, 2008 to April 15, 2008. In addition,
      the Second Amendment changes the merger consideration by adding the issuance
      to
      certain members of TATTOFF a series of preferred stock to be created by the
      Company prior to the effective time of the Merger. The Company cannot provide
      any assurances that the merger of TATTOFF will be completed. The Merger
      Agreement was filed as Exhibit 2.1 to the Current Report on Form 8-K filed
      with
      the Securities and Exchange Commission on October 1, 2007. A copy of the Second
      Amendment is attached hereto as Exhibit 2.3. The foregoing descriptions of
      the
      Merger and the Merger Agreement, as amended, and the transactions contemplated
      thereby do not purport to be complete and are qualified in their entirety by
      reference to the complete texts of the Merger Agreement, as
      amended.





2


TATTOFF
      was organized under the laws of the state of California in 2004. TATTOFF is
      a
      provider of marketing and practice management services to physicians who perform
      tattoo removal, hair removal services (regardless of method) and laser-based
      skin care services. TATTOFF endeavors to develop laser center sites and to
      provide turnkey marketing services, human resources and staffing services,
      patient management services, technical solutions, office management and other
      non-medical services to the physicians and medical staff at each of its laser
      centers. TATTOFF owns the registered trademark, Dr. TATTOFF, and licenses the
      use of the trademark as part of the management services provided to physicians.
      These services are provided directly to the physicians or to their medical
      corporations, medical groups or other affiliated entities. TATTOFF currently
      has
      three laser centers in Southern California: Beverly Hills, Irvine and Encino.
      For the fiscal year ended December 31, 2006 TATTOFF had revenues of
      approximately $947,000 and a net loss of approximately $(693,000). TATTOFF's
      principal executive offices are located at 8447 Wilshire Boulevard, Suite 102,
      Beverly Hills, CA 90211.




Due
      to
      the Company’s intent to remain a shell corporation until a merger or acquisition
      is completed, it is anticipated that its cash requirements shall be minimal,
      and
      that all necessary capital, to the extent required, will be provided by the
      Company’s sole officer, affiliates, third party advances or through a private
      offering of the Company’s equity securities. The Company also does not expect to
      acquire any plant or significant equipment.




The
      Company has no full time employees. Our sole officer has agreed to allocate
      a
      portion of his time to the activities of the Company, without compensation.
      This
      officer anticipates that the business plan of the Company can be implemented
      by
      devoting approximately 10 hours each per month to the business affairs of the
      Company and, consequently, conflicts of interest may arise with respect to
      the
      limited time commitment by such officer. The Company does not expect any changes
      in the number of employees.




Our
      affiliates have advanced our company working capital to cover expenses. Advances
      are non-interest bearing and repayable on or before 24 months from the date
      of
      the advance. Repayment of advances will not be a condition of completing the
      TATTOFF acquisition.




**Item
      3. Controls and Procedures**




Evaluation
      of disclosure controls and procedures




As
      of the
      end of the period covered by this report, we carried out an evaluation of the
      effectiveness of the design and operation of our disclosure controls and
      procedures pursuant to Exchange Act Rule 13a-15(e). This evaluation was done
      under the supervision and with the participation of our Principal Executive
      Officer and Principal Financial Officer. Based upon that evaluation, our
      Principal Executive Officer and Principal Financial Officer concluded that
      the
      design and operation of our disclosure controls and procedures are not effective
      due to the Company’s failure to timely file its quarterly reports and annual
      report with the SEC. This weakness is due to the Company’s lack of staffing, as
      the Company is a "blank check" company with one officer/employee that devotes
      limited time to the Company's business. We believe that the weakness will be
      resolved in the event the Company completes its reorganization.




3




Changes
      in internal controls




There
      were no changes in our internal controls or in other factors during the period
      covered by this report that have materially affected, or is likely to materially
      affect the Company’s internal controls over financial reporting.










4


**PART
      II. OTHER INFORMATION**




**Item
      1.**  **Legal
      Proceedings**




None.




**Item
      2.**  **Unregistered
      Sales of Equity Securities and Use of Proceeds**




None.




**Item
      3.**  **Default
      Upon Senior Securities**




None.




**Item
      4.**  **Submission
      of Matters to a Vote of Securities**




None.




**Item
      5.**  **Other
      Information**




During
      January, 2008 the Company issued an aggregate of 4,667 restricted shares of
      its
      common stock to 6 accredited investors and received gross proceeds of $28,002.
      The proceeds shall be used for working capital purposes. No commissions or
      fees
      were paid in connection with the offering. The shares were issued under the
      exemption from registration provided by Section 4(2) of the Securities Act.
      The
      investors received current information concerning the Company and had the
      opportunity to ask questions about the Company. The certificates representing
      the shares contain a legend restricting their transferability absent
      registration or applicable exemption.





On
      February 4, 2008, the Company’s Board of Directors approved a 55.5 for 1 pro
      rata share dividend (“Dividend”) to its shareholders to be effected on or about
      February 6, 2008 (“Dividend Date”), whereby each issued and outstanding share of
      the Company’s common stock as of the Dividend Date will receive 55.5 shares of
      the Company’s common stock for each share of common stock held by such
      shareholder on the Dividend Date. No fractional shares will be issued and
      instead will be rounded up to the nearest whole share.





**Item
      6.**  **Exhibits**




Exhibits
      required by Item 601 of Regulation S-B




2.3
            Amendment
                No. 2 to Merger Agreement dated February 1,
                2008


31.1
            Form
                302 Certification of Chief Executive
                Officer


31.2
            Form
                302 Certification of Principal Financial
                Officer


32.1
            Form
                906 Certification of Chief Executive Officer and Principal Financial
                Officer




5


Signatures




Pursuant
      to the requirements of the Securities Exchange Act of 1934, the Registrant
      has
      duly caused this report to be signed on its behalf by the undersigned as a
      duly
      authorized officer of the Registrant.




Lifesciences
      Opportunities Incorporated




By: /s/
      Roland
      Perry


Roland
      Perry


Chief
      Executive Officer and


Principal
      Financial Officer





DATED:
      February 6, 2008




6